Active Ingredient History
Mecamylamine is a non-selective, non-competitive antagonist of the nicotinic acetylcholine receptors (nAChRs) that was introduced in the 1950s as an antihypertensive drug. In the United States, it was voluntarily withdrawn from the market in 2009 but was brought to market in 2013 as Vecamyl and eventually was marketed by Turing Pharmaceuticals. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hypertension (approved 1956)
Aging (Early Phase 1)
Alcoholism (Phase 3)
Alzheimer Disease (Early Phase 1)
Autistic Disorder (Phase 1)
Cognition Disorders (Early Phase 1)
Depression (Phase 3)
Depressive Disorder (Phase 2)
Depressive Disorder, Major (Phase 2)
Growth and Development (Phase 1)
Healthy Aging (Phase 1)
Macular Degeneration (Phase 2)
Macular Edema (Phase 2)
Orthostatic Intolerance (Phase 1/Phase 2)
Postmenopause (Early Phase 1)
Smoking (Phase 2)
Spinal Cord Injuries (Phase 4)
Tachycardia (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
